Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
Piero Ruggenenti(Mario Negri Institute for Pharmacological Research), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), María Ganeva(Medical University Plovdiv), Adalberto Sessa(Azienda Ospedaliera di Desio e Vimercate), Giacomina Loriga(Mario Negri Institute for Pharmacological Research), Elena Perticucci(Azienda Ospedaliero Universitaria Ospedali Riuniti), Renzo Scanziani(Azienda Ospedaliera Ospedale Civile di Legnano), Annalisa Perna(Mario Negri Institute for Pharmacological Research), Marta Turturro(Mario Negri Institute for Pharmacological Research), Ivan Nediyalkov Chakarski(Trakia University), Mirella Alpa(Ospedale San Giovanni Bosco), Carmine Zoccali(Università Campus Bio-Medico), Mariadomenica Lesti(Mario Negri Institute for Pharmacological Research), Carlo Basile, Bogdan Ene‐Iordache(Mario Negri Institute for Pharmacological Research), Daniela Leonardis, G Garini, Gianbattista Sorba(Ospedale SS. Annunziata)
Cited by 644
Related Papers
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
|The Lancet|2001|1.1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990